Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarvajit Chakravarty

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 22, 2015
MDV3100: Tritium labeling at high specific activityChang Byon, Sarvajit Chakravarty, Crist N Filer, et al.
Cancer Research|August 4, 2004
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1Gayathri Subramanian, Roderich E Schwarz, Linda Higgins, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 6, 2006
Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injuryZhihe Li, Jing Ying Ma, Irene Kerr, et al.
Pain|May 26, 2004
Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy modelSarah M Sweitzer, Satyanarayana Medicherla, Ramona Almirez, et al.
Bioorganic & Medicinal Chemistry Letters|February 10, 2007
Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitorsPierre Raboisson, Oliver Lenz, Tse-I Lin, et al.
Journal of Cardiovascular Pharmacology|September 30, 2004
p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in ratsZhihe Li, Thomas-Toan Tran, Jing Ying Ma, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 7, 2007
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammationSatyanarayana Medicherla, Mary F Fitzgerald, Dianne Spicer, et al.
European Journal of Pharmacology|July 18, 2006
Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsivenessPuneeta Nath, Sum-Yee Leung, Alison Williams, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
p38 MAPK inhibition reduces diabetes-induced impairment of wound healingSatyanarayana Medicherla, Scott Wadsworth, Breda Cullen, et al.
American Journal of Respiratory and Critical Care Medicine|November 26, 2004
Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitorPhilippe Bonniaud, Peter J Margetts, Martin Kolb, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 22, 2015
MDV3100: Tritium labeling at high specific activityChang Byon, Sarvajit Chakravarty, Crist N Filer, et al.
Cancer Research|August 4, 2004
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1Gayathri Subramanian, Roderich E Schwarz, Linda Higgins, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 6, 2006
Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injuryZhihe Li, Jing Ying Ma, Irene Kerr, et al.
Pain|May 26, 2004
Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy modelSarah M Sweitzer, Satyanarayana Medicherla, Ramona Almirez, et al.
Bioorganic & Medicinal Chemistry Letters|February 10, 2007
Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitorsPierre Raboisson, Oliver Lenz, Tse-I Lin, et al.
Journal of Cardiovascular Pharmacology|September 30, 2004
p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in ratsZhihe Li, Thomas-Toan Tran, Jing Ying Ma, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 7, 2007
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammationSatyanarayana Medicherla, Mary F Fitzgerald, Dianne Spicer, et al.
European Journal of Pharmacology|July 18, 2006
Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsivenessPuneeta Nath, Sum-Yee Leung, Alison Williams, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
p38 MAPK inhibition reduces diabetes-induced impairment of wound healingSatyanarayana Medicherla, Scott Wadsworth, Breda Cullen, et al.
American Journal of Respiratory and Critical Care Medicine|November 26, 2004
Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitorPhilippe Bonniaud, Peter J Margetts, Martin Kolb, et al.
Pageof 4